Novo Nordisk and Replicate Bioscience have announced a multi-year research collaboration that will combine Novo’s drug development expertise with Replicate’s srRNA platform to develop new therapeutic candidates for cardiometabolic diseases.  Under the terms of the agreement, Novo Nordisk will receive a defined exclusive, worldwide license to use Replicate’s srRNA platform to develop and commercialise the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!